CFO interim
Imunon, Inc. names Josh Blacher interim CFO
Imunon, Inc. reported in a Form 8-K filed June 30, 2026 that Josh Blacher was named interim Chief Financial Officer, effective July 1, 2026.
In the filing's words
As a result of Mr. Church’s retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company’s new interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm (“Danforth”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Imunon, Inc. (IMNN) |
|---|---|
| Event | Interim |
| Incoming | Josh Blacher |
| Outgoing | Jeffrey Church |
| Title in the filing | interim Chief Financial Officer |
| Effective | July 1, 2026 |
| 8-K filed | June 30, 2026 |
| Internal promotion | No |
| Prior role (per filing) | employee of Danforth, Danforth Health, Inc. |
| SEC CIK | 0000749647 |
Imunon, Inc. reported this change in a Form 8-K, Item 5.02, filed June 30, 2026. The filing's own words are quoted above.
Same industry, June 2026
8Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
4 months ago· 2026-06-30TransitionRANI
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanford
4 months ago· 2026-06-29InterimCVKD
Cadrenal Therapeutics, Inc. names John P. Sharp interim CFO
5 months ago· 2026-06-18InterimMPLT
MapLight Therapeutics, Inc. names Jonathan Gillis interim CFO
5 months ago· 2026-06-18TransitionPTPI
Petros Pharmaceuticals, Inc. CFO transition: Robert Weinstein to succeed Mitchell Arnold
5 months ago· 2026-06-15AppointmentSNSE
Sensei Biotherapeutics, Inc. appoints Brian Stephenson as CFO
5 months ago· 2026-06-12AppointmentOCUL
Ocular Therapeutix, Inc. appoints Jason Robins as CFO
5 months ago· 2026-06-04AppointmentBYSI
BeyondSpring Inc. appoints Na Li as CFO
5 months ago· 2026-06-03InterimCVKD
Cadrenal Therapeutics, Inc. names Quang X. Pham interim CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Josh Blacher? Send a correction with the primary source.